^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
JSR Life Sciences

i
Related tests:
Evidence

News

1m
Crown Bioscience completes merger with Indivumed Services (JSR Life Sciences Press Release)
"Crown Bioscience...a part of JSR Life Sciences and Japan-based JSR Corporation, today announces the complete integration of Indivumed Services. This strategic move, following the acquisition in 2023, solidifies Crown Bioscience's standing in oncology drug research and development. As a result of this merger, the Indivumed Services brand will be fully retired in February 2025."
M&A
4ms
KBI Biopharma to lead development and manufacturing of Alanis Therapeutics’ antagonistic antibody candidate (JSR Life Sciences Press Release)
"KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), announces a manufacturing contract with Alanis Therapeutics, Inc. (ATI) for the development of an innovative pre-clinical therapeutic antibody to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) blood cancers."
Licensing / partnership
12ms
Crown Bioscience achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services (Businesswire)
"Crown Bioscience...announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services...These recognitions affirm the consistent elevation in the quality and precision of Crown Bioscience's laboratory practices, placing the company among a select number of laboratories meeting the stringent CAP and ISO quality standards within preclinical and translational cancer research."
Regulatory
over1year
MEBGEN™ BRAF 3 Kit receives MHLW approval and insurance coverage as a tumor agnostic companion diagnostic (JSR Life Sciences Press Release)
"Medical and Biological Laboratories Co., Ltd...a JSR Life Sciences Company, announced that the MEBGEN™ BRAF 3 Kit, an in vitro diagnostic reagent, was approved for manufacturing and marketing by the Ministry of Health, Labour and Welfare (MHLW) on August 18, 2023, and received national health insurance coverage on November 1, 2023...With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare tumors (solid tumors including histiocytosis and hairy cell leukemia) for which treatment options are limited."
Reimbursement • Japanese regulatory
|
MEBGEN™ BRAF 3 Kit
over2years
MEBGEN BRAF Kit receives MHLW approval as companion diagnostic for use with patients with melanoma (JSR Life Sciences Press Release)
"Medical and Biological Laboratories Co., Ltd...announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022...MEBGEN™ BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma."
Japanese regulatory
|
MEBGEN™ BRAF Kit